{"id":16283,"date":"2025-06-17T06:57:00","date_gmt":"2025-06-17T06:57:00","guid":{"rendered":"https:\/\/focus.cbbc.org\/?p=16283"},"modified":"2025-06-16T14:26:13","modified_gmt":"2025-06-16T14:26:13","slug":"chinas-biotech-sector-surges","status":"publish","type":"post","link":"https:\/\/focus.cbbc.org\/chinas-biotech-sector-surges\/","title":{"rendered":"China’s Biotech Boom Signals Global Ambition"},"content":{"rendered":"\n

China\u2019s biotechnology sector is experiencing a transformative surge, marked by billion-dollar deals and a 60% stock rally in 2025, outpacing even AI-driven markets<\/strong><\/h2>\n\n\n\n

China\u2019s biotechnology sector has emerged as a formidable force, shaking off a four-year slump to become one of Asia\u2019s hottest markets. The Hang Seng Biotech Index has surged by approximately 60% in 2025, a rally that has outstripped the 17% gain in China\u2019s tech stocks, driven by the release of DeepSeek\u2019s breakthrough artificial-intelligence model in January. This phenomenon, dubbed the \u201cDeepSeek moment\u201d for biotech, reflects China\u2019s growing prowess in innovation, positioning the country as a global contender in drug development and biotechnology. The sector\u2019s rise is underpinned by significant financial investments, strategic partnerships with global pharmaceutical giants, and a robust pipeline of innovative drugs, particularly in oncology.<\/p>\n\n\n\n

The term \u201cDeepSeek moment\u201d draws from the success of DeepSeek\u2019s<\/a> R1 artificial-intelligence model, which propelled the Chinese AI startup to global prominence earlier this year. In biotech, this analogy captures the sector\u2019s rapid ascent and its potential to disrupt global markets. \u201cChina biotech is no longer just an emerging story \u2014 unlike 10 years ago \u2014 it is now a disruptive force reshaping global drug innovation,\u201d Yiqi Liu, senior investment analyst at Exome Asset Management LLC in New York told Bloomberg. This sentiment is echoed in the flurry of high-value licensing deals and initial public offerings (IPOs) that have invigorated investor confidence.<\/p>\n\n\n

\n
\"\"<\/a><\/figure>\n<\/div>\n\n\n

A notable example is the performance of companies like Akeso, a Chinese drug developer that has seen its shares climb 6.5 times their IPO price from five years ago, despite a temporary 11.8% drop following a second marketing IP for its lung cancer drug ivonescimab in April 2025. Ivonescimab, a bispecific antibody, has outperformed Merck\u2019s blockbuster drug Keytruda in phase three trials, marking a significant milestone. \u201cThe development of the new antibody drug was hailed by the mainland media last month as the biotech industry\u2019s \u2018DeepSeek moment\u2019,\u201d reported the South China Morning Post, highlighting the drug\u2019s potential to challenge global oncology standards. Akeso\u2019s partnership with Summit Therapeutics in the US to advance ivonescimab\u2019s clinical trials across 108 locations in 12 nations underscores China\u2019s ambition to compete on the global stage.<\/p>\n\n\n\n

The financial momentum is equally striking. In May 2025, eight licensing deals were reached in China\u2019s biopharma sector, with five cross-border out-licensing agreements generating over \u00a31 billion upfront and a potential \u00a36.5 billion including milestones, according to posts on X. This represents a significant increase from April 2025, which saw six deals with \u00a3141 million upfront and \u00a32.35 billion in total potential value. These figures reflect a growing appetite among global pharmaceutical companies for Chinese-developed drugs. For instance, Bristol-Myers Squibb agreed to pay Germany\u2019s BioNTech SE up to \u00a38.45 billion to license a cancer drug originally developed by China\u2019s Biotheus Inc, which BioNTech had acquired for \u00a3590 million in 2023. Such deals highlight the economic allure of China\u2019s biotech innovations.<\/p>\n\n\n\n